Meanwhile, in a study by Thomann et al., liposomal constructs co-delivering peptide epitopes and TLR agonists were developed to induce a specific anti-tumor immune response against ErbB2 protein-expressing tumor cells [205]. This evidence concerns the gene ERBB2 and neoplasm.